Laminar Pharma
Contact information
- A. Health Biotechnology
- Areas of activity
- Biodrugs
- Biomarkers
- In vitro diagnostics
- Therapeutic areas
- Genetic and rare diseases
- Inflammatory diseases
- Immunology
- Oncology
- Central nervous system
- Metabolic disorders / Endocrinology
We are a Spanish biopharmaceutical company committed to secure the health translation. Our goal is to develop new and safe generation of biomedical therapies with a social and sustainable impact.
Our mission is to discover, develop and commercialize innovative and pioneering solutions based on new mechanisms such as Membrane Lipid Therapy.
Values statements: Provide benefits of Meliterapia to the global society contributing to improve pharmacological treatments for serious diseases.
Rationally designed compounds that act through Membrane Lipid Therapy, an innovative therapeutic strategy based on the regulation of the lipid composition of membranes as a potential treatment for diseases such as cancer, Alzheimer's disease, metabolic, infectious and inflammatory diseases.
- WO03030891. Use of hydroxyoleic acid and similar compounds in the production of medicaments.
- WO2010/066931. Alpha-derivatives of cis-monounsaturated fatty acids for use as medicines.
- WO/2010/106211. Use of derivatives of polyunsaturated fatty acids as medicaments.
- WO2013050644. Enantiomers of 2-hydroxy derivatives of fatty acids.
- WO2016/062746. Method for the synthesis of hydroxy-triglycerides and uses thereof for the prevention and treatment of diseases.
Red Biotechnology: Next-generation drugs in Oncology, CNS infectious and inflammatory diseases.
Biotech Sanitaria
Product / Service | Type | Therapeutic area | Development phase |
---|---|---|---|
LAMPEC11 | Biodrugs/ Drugs | Oncología | R&D |
LAMAC2 | Biodrugs/ Drugs | Enfermedades infecciosas | P I |
LAM561 | Biodrugs/ Drugs | Oncología | P III |
LAM226A1 | Biodrugs/ Drugs | Sistema nervioso central | Preclinical |
LAM182 | Biodrugs/ Drugs | Oncología | P II |
LAM181 | Biodrugs/ Drugs | Sistema nervioso central | P II |
LAM30171 | Biodrugs/ Drugs | Oncología, Trastornos metabólicos / Endocrinología | R&D |
LAM204A1 | Biodrugs/ Drugs | Inmunología, Enfermedades cardiovasculares y sistema circulatorio | R&D |
LAM205A1 | Biodrugs/ Drugs | Enfermedades cardiovasculares y sistema circulatorio, Sistema nervioso central, Trastornos metabólicos / Endocrinología | R&D |
Product / Service | Type | Development phase |
---|---|---|
Membrane-Lipid Therapy (MLT) | Enabling Technologies | Clinical Validation |